New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 12, 2014
19:23 EDTABBV, ENTAEnanta reports detailed results from Turquoise ll study
Enanta Pharmaceuticals (ENTA) announced that detailed results from AbbVie’s (ABBV) pivotal phase 3 TURQUOISE-II study, will be presented as a late-breaking oral presentation at the International Liver Congress, ILC, which is the 49th Annual Meeting of the European Association for the Study of the Liver, EASL. Results from the TURQUOISE-II study were featured in the ILC press conference and were published on-line in the New England Journal of Medicine. The TURQUOISE-II study reports results from AbbVie’s investigational three direct-acting antiviral regimen containing ABT-450, Enanta’s lead protease inhibitor discovered through Enanta’s collaboration with AbbVie. The regimen consists of boosted protease inhibitor ABT-450/ritonavir, NS5A inhibitor ABT-267, and non-nucleoside polymerase inhibitor ABT-333. TURQUOISE-II is a global, multi-center, randomized, open-label study evaluating the efficacy and safety of 12 weeks or 24 weeks of treatment with AbbVie's three direct-acting antiviral regimen with ribavirin, RBV, in adult patients with genotype 1, GT1, chronic hepatitis C virus, HCV, infection with compensated liver cirrhosis. Patients achieved sustained virologic response rates 12 weeks post-treatment, SVR12, of 91.8% and 95.9% in the 12-week and 24-week treatment arms, respectively. Patients in the study were either new to therapy or treatment-experienced, failed previous treatment with pegylated interferon and RBV.
News For ENTA;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
09:10 EDTABBVAbbVie initiates study of Imbruvica for lymphoma
Subscribe for More Information
09:02 EDTABBVSeattle Genetics says data from ADC programs to be presented at ASCO
Seattle Genetics (SGEN) announced that data from multiple proprietary and collaborator antibody-drug conjugate programs will be highlighted in more than 10 sessions at the American Society of Clinical Oncology 2015 Annual Meeting being held May 29 to June 2, 2015 in Chicago, IL. Presentations will feature data from several corporate and investigator-sponsored trials with ADCETRIS, including additional analyses from the phase 3 AETHERA clinical trial and updated data in frontline diffuse large B-cell lymphoma. In addition, the company’s ADC collaborators, including Genentech (RHHBY), AbbVie (ABBV), Genmab and Agensys, will report data from clinical programs using Seattle Genetics’ ADC technology. Seattle Genetics will also present preclinical data from its novel SEA-CD40 immuno-oncology candidate currently being evaluated in a phase 1 clinical trial. Seattle Genetics is evaluating its ADC technology broadly through ADCETRIS, proprietary pipeline and collaborator programs. The company is leading the field in developing ADCs, a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. In addition, Seattle Genetics is building on expertise in empowered, targeted approaches for the treatment of cancer in advancing its proprietary sugar-engineered antibody technology, a novel technology designed to increase the potency of monoclonal antibodies through glycoengineering which may lead to an improved antitumor immune response.
07:25 EDTABBVEuro Renal Association / Euro Dialysis & Transplant Assoc to hold conference
52nd ERA-EDTA Congress is being held in London, England on May 28-31.
06:21 EDTABBVAbbVie coverage resumed with an Equal Weight at Morgan Stanley
Subscribe for More Information
May 27, 2015
06:57 EDTABBVAbbVie enters into ASR with Morgan Stanley to repurchase $5B of stock
AbbVie (ABBV) said in a regulatory filing that on May 26, it entered into an accelerated share repurchase agreement with Morgan Stanley (MS) to repurchase $5B of AbbVie’s common stock. Morgan Stanley is expected to make an initial delivery of approximately 68 million shares of AbbVie’s common stock on May 27, which represents 90% of the prepayment amount divided by the closing price of AbbVie’s common stock on May 26. At settlement of the agreement, Morgan Stanley may be required to deliver additional shares of AbbVie’s common stock to AbbVie or, under certain circumstances, AbbVie may be required to deliver shares of its common stock or may elect to make a cash payment to Morgan Stanley. The total number of shares of AbbVie’s common stock to be repurchased under the agreement will be based on the daily volume-weighted average price of AbbVie’s common stock during the term of the transaction, less a discount and subject to adjustment pursuant to the terms of the agreement. The final settlement of the transactions under the agreement is expected to occur before the end of 4Q15 and may be accelerated at the option of Morgan Stanley.This agreement was entered into pursuant to AbbVie’s previously disclosed share repurchase authorization and in connection with AbbVie’s previously announced acquisition of Pharmacyclics, which was completed on May 26.
06:25 EDTABBVAbbVie reinstated with an Overweight at JPMorgan
JPMorgan reinstated its Overweight rating on shares of AbbVie and raised its price target for shares to $75 from $73. The firm views the valuation as "inexpensive" and views the Pharmacyclics acquisition as adding a "solid" growth platform.
May 26, 2015
19:16 EDTABBV, ENTAEnanta says may receive $30M milestone payment from AbbVie upon Japan approval
In reference to the release of GIFT-1 study data, Enanta (ENTA) stated that upon commercialization regulatory approval [sic] in Japan of AbbVie's (ABBV) treatment regimen related to GIFT-1, Enanta will be entitled to a $30M milestone payment from AbbVie. In addition, Enanta will be eligible to receive annually tiered royalties, ranging from the low double digits up to 20%, on AbbVie’s aggregate net sales of all paritaprevir-containing regimens, including 45% of AbbVie’s worldwide net sales of any two direct-acting antivirals regimen.
19:07 EDTENTA, ABBVAbbVie presents phase 3 GIFT-I data, says achieved primary endpoint
Subscribe for More Information
10:46 EDTABBVAnthem sued for denying coverage for Gilead's Harvoni, WSJ says
Subscribe for More Information
08:32 EDTABBVAbbVie completes acquisition of Pharmacyclics
Subscribe for More Information
08:03 EDTABBVInfinity Pharmaceuticals reports preclinical data for duvelisib
Subscribe for More Information
May 22, 2015
08:00 EDTABBVAbbVie announces expiration of HSR waiting period for Pharmacyclics acquisition
AbbVie (ABBV) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for AbbVie's purchase of Pharmacyclics (PCYC) has expired today. The expiration satisfies the exchange offer condition with respect to the approvals and clearances required under antitrust laws. Assuming that the other customary exchange offer conditions are satisfied, including a minimum tender of at least a majority of outstanding Pharmacyclics shares, it is expected that the exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics will expire today at 5:00 p.m., New York City time, without any further extension.
May 21, 2015
08:04 EDTABBVAbbVie announces offer consideration for acquisition of Pharmacyclics
AbbVie (ABBV) announced the per share offer consideration amounts pursuant to its previously announced offer to acquire each outstanding share of common stock of Pharmacyclics (PCYC) for a mix of cash and AbbVie common stock, as described in the Registration Statement on Form S-4 filed with the SEC by AbbVie on March 23, 2015, as amended. The mixed consideration will consist of $152.25 in cash and 1.6639 shares of AbbVie common stock and, subject to proration, the all-stock consideration will consist of 3.9879 shares of AbbVie common stock.
07:58 EDTABBVDeutsche sees AbbVie shares getting to $80 over summer
Deutsche Bank sees pipeline readouts over the summer pushing shares of AbbVie to $80. The firm keeps a Buy rating on the stock with an $80 price target after meting with management.
07:37 EDTABBVPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
09:07 EDTABBVJohnson & Johnson says exploring eight new indications for Imbruvica
Imbruvica is jointly developed and commercialized by Pharmacyclics (PCYC) and Johnson & Johnson (JNJ) subsidiary Janssen Biotech. AbbVie (ABBV) is in the process of acquiring Pharmacyclics.
07:21 EDTABBVUBS to hold a conference
Subscribe for More Information
May 19, 2015
08:57 EDTABBVLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
May 18, 2015
15:07 EDTENTAEnanta management to meet with JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use